Clinical trials of adult acute nonlymphocytic leukemia: evidence of progress

Lewis, Jerry P.

doi:10.1016/0305-7372(85)90004-0

Cited by 11 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may have influenced our complete remission rate and remission duration which are inferior to overall literature results of complete remission rates of 55% to 88%, median remission durations of 31 to 47 weeks, relapses within 1 to 2 years, and 2-year survivals of 20% to 40%. 16,17 Our results also reflect the rather high rate of documented septic complications, and especially fungemias.…”

Section: Discussionsupporting

confidence: 70%

“…It differs significantly from all reported series from Western centers. [3][4][5][6][7] The response of ANLL to various induction chemotherapy regimens combining cytarabine, daunorubicin, and thioguanine, in the doses and schedules used in our patients, has been reviewed in the literature with the conclusions that no one way is significantly better, nor could be recommended more than the others [14][15][16][17] ; this has allowed us to group our patients together. No attempt was made to compare them because of small numbers.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adult Acute Nonlymphocytic Leukemia in Saudi Arabia: Experience at King Khalid University Hospital in Riyadh

et al. 1989

View full text Add to dashboard Cite

Twenty-two adult patients with acute nonlymphocytic leukemia (ANLL) were analyzed. There were 15 males (68%) and 7 females (32%). Their median age was 42 years. Thirty-six percent had acute myelomonocytic leukemia (M4), and 46% had acute monocytic leukemia (M5), according to the French-American-British classification. Of 17 patients who received intensive combination chemotherapy, 47% achieved complete remission. Of the subgroup of 14 new and previously untreated patients, the complete remission rate was 57%. The rest of the patients died of septic complications. We report an increased ratio of M4 and M5 in ANLL in Saudi Arabia and an increased rate of severe septic and fungal complications.

show abstract

Section: Discussionsupporting

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Adult Acute Nonlymphocytic Leukemia in Saudi Arabia: Experience at King Khalid University Hospital in Riyadh

et al. 1989

View full text Add to dashboard Cite

show abstract

“…A review of some recent publications showed a combined complete remission (CR) rate of 36% [ 151. This is at the lower end of a range of 30-83% given in a recent comprehensive review of chemotherapy for adult AML [20] and certainly less than is commonly expected with modern chemotherapy for this disease. Although a number of remissions of more than 2 years have been reported in SAML, it is difficult to tell to what degree the proportion of such remissions differs from that seen in AML arising de novo [5,10,12,2 1,221.…”

Section: Discussionmentioning

confidence: 99%

Double autologous bone marrow transplantation for acute myelogenous leukemia in a patient treated for Hodgkin's disease

Russell

Jones

Houwen

et al. 1989

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

A 30-year-old man developed acute myelogenous leukemia nearly 3 years after treatment of Hodgkin's disease with radiation and three chemotherapy combinations. Remission was induced with one cycle of high-dose Ara-C therapy. Three cycles of consolidation chemotherapy were given. The patient then had two autologous bone marrow transplants, the first after conditioning with 5 Gy total body irradiation, the second after Melphalan 140 mg/m2. The procedures were well tolerated, although hematological reconstitution was very slow after the second autotransplant. The patient has been disease-free for over 4 years. Such patients may be more vulnerable to transplant-related complications because of their previous exposure to chemotherapy and radiation, which may damage several organs including the bone marrow. This report demonstrates that patients with secondary acute myelogenous leukemia may tolerate a double autotransplant procedure and achieve durable remissions.

show abstract

Bone marrow transplantation for acute monocytic leukemia following the treatment of hodgkin's disease

Russell¹,

Houwen²,

Ruether³

et al. 1986

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

A 32-year-old woman developed acute monocytic leukemia within a year of treatment for Hodgkin's disease with chemotherapy and radiation. Residual leukemia was present in the bone marrow after two induction courses of high-dose Ara-C. She received a bone marrow transplant from an HLA- and DR-identical sister and remains in complete remission more than 2 years after transplantation. Only one other instance of a remission greater than 2 years after transplantation for secondary acute leukemia could be found in the literature. Although bone marrow transplantation may be carried out successfully in these patients, it is possible that they may be more vulnerable to transplant-related complications because of their previous exposure to chemotherapy and radiation. Only further study can clarify this matter and determine the best time for the procedure and which regimen should be used.

show abstract

Clinical trials of adult acute nonlymphocytic leukemia: evidence of progress

Cited by 11 publications

References 34 publications

Adult Acute Nonlymphocytic Leukemia in Saudi Arabia: Experience at King Khalid University Hospital in Riyadh

Adult Acute Nonlymphocytic Leukemia in Saudi Arabia: Experience at King Khalid University Hospital in Riyadh

Double autologous bone marrow transplantation for acute myelogenous leukemia in a patient treated for Hodgkin's disease

Bone marrow transplantation for acute monocytic leukemia following the treatment of hodgkin's disease

Contact Info

Product

Resources

About